Skip to content
value.today

Pacegenix, Inc.

Total raised
$23 M
1 round on record
Latest round
$23 M
Mar 2026
First round on record
Mar 2026
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Pacegenix, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2026$23 MNo. 1$10 to $50 million

Pacegenix, Inc.: Raise no. 1, Mar 2026

Investors in this round

15 investors had bought by the notice of Mar 26, 2026: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$23 M of $23 M offered
Smallest investment taken
no minimum stated
What was sold
equity, debt, other: SAFE Convertible Notes
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$577,517
Finders' fees
none
Paid to its own people
$600,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Frank Neville Grazzini, II · Executive Officer
  • Jay Glenn Wohlgemuth · Executive Officer, Director
  • Fredric Neville Eshelman · Director
  • Raymond Glenn Tabibiazar · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • LifeSci Capital, LLC (CRD 168404) · broker-dealer LifeSci Capital, LLC (CRD 168404) · New York, New YorkSold in CA, NC, NY, TN, and outside the US

Remarks in the notice

  • On fees: “Includes equity issued as sales compensation per engagement letter dated 2/10/25: 300,000 shares issued to LifeSci at or around 2/10/25 at $0.0001 per share, fair market value of $30, consistent with Rule 501(c) and Form D Item 13 valuation methodology.”

Signed by Jay Glenn Wohlgemuth, Ceo. Source: SEC Form D, newest notice filed Mar 26, 2026. Read the notice at the SEC.

equity, debtSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Pacegenix, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2026).

    SEC Form D · Mar 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Mar 2026

That is all the official record says: Pacegenix, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Pacegenix, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 15 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Pacegenix, Inc.
NameRoleNamed in
Frank Neville Grazzini, IIExecutive officerMar 2026
Jay Glenn WohlgemuthExecutive officerMar 2026
Fredric Neville EshelmanDirectorMar 2026
Jay Glenn WohlgemuthDirectorMar 2026
Raymond Glenn TabibiazarDirectorMar 2026